Tailstorm Health Inc. dba Medivant Health
Has Tailstorm Health Inc. dba Medivant Health received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Tailstorm Health Inc. dba Medivant Health a warning letter naming semaglutide and tirzepatide, dated Apr 8, 2025, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” FDA has posted a close-out letter for that letter.
FDA records in this index name Tailstorm Health Inc. dba Medivant Health on Apr 8, 2025. It is listed on FDA’s registered 503B outsourcing facility list: Tailstorm Health Inc., Chandler, AZ.
- Type named in FDA records
- Compounding pharmacy, 503B outsourcing facility
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Apr 8, 2025
- 503B location
- Chandler, AZ
- 503B last inspection
- Aug 28, 2026
- Form 483 issued
- Yes
- Action on last inspection
- Open
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Apr 8, 2025 | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | Close-out letter, Apr 14, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Apr 8, 2025: … evidence that: 1. Your facility’s drug products, such as Semaglutide Injection 1mg/0.2ml and Tirzepatide Injection … Full letter
Drug recalls
No openFDA drug recall reports in this index.
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists 2 facilities under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Tailstorm Health, Inc., Chandler, AZ (503B)
5 listed actions, including 3 Form 483s and 1 untitled letter (2021 to 2026).
| Document | |||
|---|---|---|---|
| Aug 28, 2026 | Form 483 | 483 Issued 08/28/2026 | fda.gov |
| May 23, 2025 | Form 483 | 483 Issued 05/23/2025 | fda.gov |
| Oct 23, 2023 | FMD-145 letter | FMD-145 Letter Issued 10/23/2023 | Not linked by FDA |
| Jun 17, 2022 | Untitled letter | Untitled Letter Issued 06/17/2022 | FDA copy (archived) |
| Jul 21, 2021 | Form 483 | 483 Issued 07/21/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
Tailstorm Health, Inc., Phoenix, AZ (503B)
6 listed actions, including 2 Form 483s, 1 warning letter and 1 warning letter close-out (2024 to 2026).
| Document | |||
|---|---|---|---|
| Mar 23, 2026 | Warning letter close-out | Warning Letter Close Out Issued 03/23/2026 | fda.gov |
| Mar 20, 2026 | FMD-145 letter | FMD-145 Letter Issued 03/20/2026 | Not linked by FDA |
| Mar 19, 2026 | FMD-145 letter | FMD-145 Letter Issued 03/19/2026 | Not linked by FDA |
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Apr 8, 2025 | Warning letter | Warning Letter Issued 04/08/2025 | fda.gov |
| Oct 10, 2024 | Form 483 | 483 Issued 10/10/2024 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Tailstorm Health Inc., Chandler, AZ, Tailstorm Health, Inc., Phoenix, AZ.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 11 products naming semaglutide and tirzepatide under the labeler name “Tailstorm Health INC”, matched to this company page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (11). The compounded product reports cover FDA reporting periods 2024-2 to 2025-1.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 81483-0045 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .25 mg/.05 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0046 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .5 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0047 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0048 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1.7 mg/.22 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0049 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 2.4 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0050 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 2.4 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0051 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 5 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0052 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 7.5 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0053 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 10 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0054 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 12.5 mg/.25 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0055 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 15 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Apr 8, 2025
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.